<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Avanafil</strong></td></tr><tr><th>Accession Number</th><td><strong>DB06237</strong></td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Avanafil is a new phosphodiesterase-5 inhibitor that is faster acting and more selective than other drugs belonging to the same class. Chemically, it is a derivative of pyrimidine and is only available as the S-enantiomer. <span class="caps">FDA</span> approved on April 27, 2012.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB06237/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB06237/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06237.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06237.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06237.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06237.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB06237.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB06237">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>TA-1790</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Stendra </td><td>Vivus </td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>CAS number</th><td>330784-47-9</td></tr><tr><th>Weight</th><td>Average: 483.951<br>Monoisotopic: 483.17856544</td></tr><tr><th>Chemical Formula</th><td>C<sub>23</sub>H<sub>26</sub>ClN<sub>7</sub>O<sub>3</sub></td></tr><tr><th>InChI Key</th><td>WEAJZXNPAWBCOA-INIZCTEOSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C23H26ClN7O3/c1-34-19-6-5-15(10-18(19)24)11-27-21-17(22(33)28-13-20-25-7-3-8-26-20)12-29-23(30-21)31-9-2-4-16(31)14-32/h3,5-8,10,12,16,32H,2,4,9,11,13-14H2,1H3,(H,28,33)(H,27,29,30)/t16-/m0/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-{[(3-chloro-4-methoxyphenyl)methyl]amino}-2-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-N-(pyrimidin-2-ylmethyl)pyrimidine-5-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=C(Cl)C=C(CNC2=C(C=NC(=N2)N2CCC[C@H]2CO)C(=O)NCC2=NC=CC=N2)C=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Diazines</td></tr><tr><th>Subclass</th><td>Pyrimidines and Pyrimidine Derivatives</td></tr><tr><th>Direct parent</th><td>Pyrimidinecarboxamides</td></tr><tr><th>Alternative parents</th><td>Anisoles; Alkyl Aryl Ethers; Aminopyrimidines and Derivatives; Chlorobenzenes; Aryl Chlorides; Pyrrolidines; Tertiary Amines; Secondary Carboxylic Acid Amides; Carboxylic Acids; Polyamines; Enolates; Secondary Amines; Primary Alcohols; Organochlorides</td></tr><tr><th>Substituents</th><td>phenol ether; anisole; aminopyrimidine; alkyl aryl ether; chlorobenzene; aryl chloride; benzene; aryl halide; pyrrolidine; secondary carboxylic acid amide; tertiary amine; carboxamide group; primary alcohol; carboxylic acid derivative; enolate; ether; polyamine; carboxylic acid; secondary amine; organochloride; amine; organohalogen; alcohol; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the pyrimidinecarboxamides. These are compounds containing a pyrimidine ring which bears a carboxamide.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Treatment of erectile dysfunction in males. </td></tr><tr><th>Pharmacodynamics</th><td>Avanafil is a strong, competitive inhibitor of PDE5. It is also 100-times more potent for PDE5 than PDE6. The IC50 of avanafil is 5.2 nM. Compared to other PDE5 inhibitor like sildenafil and vardenafil, it is 16- and 21-fold more selective for PDE5 respectively. Avanafil does not bind to PDE6 and PDE11 to a considerable degree. The impact of this finding is that avanafil is less likely to cause side effects such as visual disturbances and myalgia. These are side effects that patients on sildenafil or tadalafil are more likely to experience.  Furthermore, single oral doses of avanafil (200 mg) administered to healthy male volunteers resulted in mean changes from baseline in systolic/diastolic blood pressure of -5.3/-3.7 mmHg at 1 hour after dosing. Avanafil does not causes changes in QTc interval or ventricular repolarization. </td></tr><tr><th>Mechanism of action</th><td>Avanafil is a selective phosphodiesterase 5 (PDE5) enzyme inhibitor used for the treatment of erectile dysfunction caused by diabetes, age induced oxidative stress or other complications. Avanafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by avanafil enhances erectile function by increasing the amount of cGMP.</td></tr><tr><th>Absorption</th><td>Avanafil is rapidly absorbed and does not accumulate following multiple doses. 
Tmax = 30 - 45 minutes;
Time to peak response = 10 minutes (20 minutes shorter than sildenafil) </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>99% bound to plasma protein. Protein binding is independent of total drug concentrations, age, renal and hepatic function.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Avanafil is hepatically metabolized primarily by the enzyme, CYP3A4. Two major metabolites are formed, M4 and M16. M4 has 4% of the pharmacologic activity of avanafil. M16 is an inactive metabolite.  </p></td></tr><tr><th>Route of elimination</th><td>After oral administration, avanafil is excreted as metabolites predominantly in the feces (approximately 62% of administered oral dose) and to a lesser extent in the urine (approximately 21% of the administered oral dose). </td></tr><tr><th>Half life</th><td>Mean elimination half-life = 5.36 - 10.66 hours </td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Avanafil is generally well tolerated. The most commonly reported adverse event are headache and facial flushing. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9958</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.7165</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.61</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.672</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6724</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9038</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5282</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7215</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.795</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.6184</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5841</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7495</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5892</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.549</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5277</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6096
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8809
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9929
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5077 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6671
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8671
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>50 mg; 100 mg; 200 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB08822">Azilsartan medoxomil</a></td><td>Pharmacodynamic synergist- increases effects. </td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Co-administration with avanafil resulted in an approximate 5.7% increase in AUC0-inf and 5.2% decrease in Cmax of rosiglitazone.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Co-administration with the moderate CYP3A4 inhibitor erythromycin resulted in an approximate 3.6-fold increase in AUC0-inf and 2.0-fold increase in Cmax of avanafil.
</td></tr><tr><td><a href="/drugs/DB00883">Isosorbide Dinitrate</a></td><td>Additive vasodilation. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01020">Isosorbide Mononitrate</a></td><td>Additive vasodilation. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Co-administration with the strong CYP3A4 inhibitor ketoconazole resulted in an approximate 13-fold increase in AUC0-inf and 3.1-fold increase in Cmax. </td></tr><tr><td><a href="/drugs/DB00727">Nitroglycerin</a></td><td>Additive vasodilation. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00338">Omeprazole</a></td><td>Nineteen healthy male volunteers received a single 40 omeprazole delayed-release capsule once daily for 8 days (Days 1-8), and a single 200 mg avanafil on Day 8. Twelve hour pharmacokinetics of omeprazole on Days 7 and 8 were compared. Co-administration with avanafil resulted in an approximate 5.9% increase in AUC0-inf and 8.6% increase in Cmax of omeprazole. </td></tr><tr><td><a href="/drugs/DB00503">Ritonavir</a></td><td>Co-administration with the strong CYP3A4 inhibitor ritonavir resulted in an approximate 13-fold increase in AUC0-inf and 2.4-fold increase in Cmax of avanafil. </td></tr><tr><td><a href="/drugs/DB00412">Rosiglitazone</a></td><td>Co-administration with avanafil resulted in an approximate 2.0% increase in AUC0-inf and 14% decrease in Cmax of rosiglitazone. </td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Co-administration with avanafil resulted in an approximate 1.6% increase in AUC(0-inf) and 5.2% decrease in Cmax of S-warfarin.
</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>When taken with a high-fat meal, time to maximum plasma concentration is prolonged- Tmax = 1 hour 20 minutes</li></ul></td></tr></tbody></table>